39.9 F
New York
Monday, January 17, 2022

Matinas CEO Jerome D. Jabbour Highlights Company Pipeline – WSM Interview with Jason Lin

直击美股

Matinas BioPharma (NYSEAMERICAN: MTNB) CEO, Jerome D. Jabbour, sits down with WSM’s Jason Lin at NYSE to discuss its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions, as well as MAT2203, the medicine to treat serious invasive fungal infections.

更多相关

- 财经媒体实习项目 -spot_img

最新文章

January 16, 2022

January 15, 2022

January 14, 2022

January 13, 2022

Market Direction Is Up